CellsBin is a Branford, Connecticut-based tech-bio company pioneering Rare-Cell Biology, the study of the rare cells that shape human health. Its Rare-Cell Intelligence platform combines advanced microfluidics, patented multimodal imaging, single-cell analysis and artificial intelligence to detect, characterize and monitor rare cells at scale, making biological signals that conventional methods miss visible, measurable and actionable. Initial applications focus on cell and gene therapy monitoring and hematologic cancers, and the company operates its headquarters and a CLIA laboratory in Branford while partnering with academic and medical centers including Yale University.
1
Round
1
Industry
4
Tags
Sep 22, 2026
Latest raise
Funding activity · 1 round
Sep 22, 2026
$-1
Series A
Led by 108 BioCapital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
